Monoclonal antibodies for all proteins

Abmart’s goal is to enable every protein to have a standard set of monoclonal antibodies optimal for all possible applications. With priopertary SEAL™ technology and a scalable monoclonal antibody development process, Abmart offers new monoclonal antibody discovery for any protein predicted by DNA sequence at a cost under $1000, in 3 months and with a success rate of >95%.

Abmart’s approach has fundamentally changed the conventional “trial-and-error” antibody research process. Continuing technology and process innovations will deliver even lower cost and faster discovery time for monoclonal antibodies. The “mass discovery” of monoclonal antibodies will bring a revolution in biomedical research and drug discovery to enable industrial scale discoveries of novel therapeutic targets, diagnostic biomarkers and therapeutic antibodies.

Abmart in numbers:

  • Started in 2007 by experienced life science entrepreneurs returned from overseas
  • With 220 employees, Abmart is one of the largest and fastest growing biotechnology companies in China
  • Now has >1000 customers worldwide
  • 3000 SEAL™ libraries successfully delivered in 2011
  • A 30,000 sqf facility consisting of production and animal facilities in Shanghai
  • A 120,000 sqf facility (currently under construction) will become the largest monoclonal antibody discovery center in 2012